CCK-antagonists in a rat exposed to acute stress: Implication for anxiety associated with post-traumatic stress disorder

Depression and Anxiety

Volumn 10, Issue 1, 1999, Pages 8-17

  Cohen, Hagit ^a   Kaplan, Zeev ^a   Kotler, Moshe ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Animal model; Anxiety; Anxiety related behavior; Cholecystokinin; Post traumatic stress disorders

Indexed keywords

CHOLECYSTOKININ; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BEHAVIOR; CONTROLLED STUDY; MALE; NEUROBIOLOGY; NONHUMAN; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RAT;

EID: 0032802417     PISSN: 10914269     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1520-6394(1999)10:1<8::aid-da2>3.0.co;2-#     Document Type: Article

References (35)

1. Adamec RE, Shallow T. 1993. Lasting effects on rodent anxiety of a single exposure to a cat. Physiol Behav 54:101-109.
2. Adamec RE, Shallow T, Budgell J. 1997. Blockade of CCKB but not CCK\ receptor before and aftert the stress of predator exposure prevent lasting increases in anxiety-like behavior: Implication for anxiety associated with posttraumatic stress disorder. Behav Neurosci 111:435-449.
3. Adams JB, Pyke RE, Costa J, Cutler NR, Schweizer E, Wïlcox CS, Wisselink PG, Greiner Al, Pierce MW, Parde AC. 1995. A double-blind, placebo-controlled study of a CCK-B receptor antagonist CI-988, in panic with generalized anxiety disorder. J Clin Psychopharmacol 15:422-434.
4. Belzung C, Pineau N , Beuzen A, Misslin R. 1994. PD135158, a CCK-antagonist, reduces "state", but not "trait" anxiety in mice. Pharmacol Biochem Behav 49:433-436.
5. Bickerdike MJ, Alarsden CA, Dourish CT, Fletcher A. 1994. CCK antagonist effects in the rat elevated zero-maze model of anxiety influence of 5-HT re-uptake blockade. Eur J Pharmacol 271: 403-411.
6. Bourin M, Alalinge M, Bradwejn J. 1996. Two faces of cholecystokinin: anxiety and schizophrenia. Fundam Clin Pharmacol 10:116-126.
7. Bradwejn J, Koszycki D, Aletterissian G.. 1990. Cholecystokinin tetrapeptide induces panic attacks in patients with panic disorder. Can} Psychiatry- 35:83-85.
8. Bradwejn J, Koszycki D, Paradis M, Reece P, Hinton J, Sedman A. 1995. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers. Biol Psychiatry 38:742-746.
9. Bradweij J, Koszycki D, Couetoux du Tertre A, Van Alegen H, der Boer J, Westenberg H. 1994. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365, 260, a central cholecystokinin receptor antagonist in patients with panic disorder. Arch Gen Psychiatry 51:486-493.
10. Cohen H, Friedberg S, Kotler M, Kaplan Z. 1997. Interaction of CCK-4 induced anxiety and post-cat exposure anxiety in rats. Depression Anxiety 4:144-145.
11. Costall B, Domeney AA1, Hughes J, Kelly ME, Naylor RJ, Woodruff GN. 1991. Anxiolytic effects of CCK-B antagonists. Neuropeptides 19:65-73.
12. Crawley JN. 1994. Interactions between cholecystokinin and other neurotransmitter systems. In: Bradwejn J, editor. Cholecystokinin and anxiety, from neuron to behavior. Biomédical Publishers, CRC Press.
13. Dawson GR, Rupniak NM, Iversen SD, Curnow R, Tye S, Stanhope KJ, Tricklebank MD. 1995. Lack of effect of CCK-B receptor antagonists in ethnological and conditioned animal screens for anxiolytic drugs. Psychopharmacol Berl 121:109-117.
14. de Alontigny C. 1989. Cholecystokinin tetrapeptide induces panic-like attacks in healthy subjects. Arch Gen Psychiatry 46:511-517.
15. Derrien M, Durieux C, Roques BP. 1994. Antidepressant-Iike effects of CCKB antagonists in mice: antagonism by naltridone. Br J Pharmacol 111:956-960.
16. File SE. 1993. The interplay of learning and aaxiety in the elevated plus maze. Behav Brain Res 58:199-202.
17. Harro J, Lang A, Vasar E. 1990a. Long-term diazepam treatment produces changes in cholecystokinin receptor binding in rat brain. EurJ Pharmacol 180:77-83.
18. Harro J, P old M, Vasar E. 1990b. Anxiogenic-like action of caerulein, a CCK-8 receptor agonist, in the mouse: influence of acute and subchronic diazepam treatment. Naunyn Schmiedebergs Arch Pharmacol 341:62-67.
19. Harro J, Vasar E. 1991. Evidence that CCK receptors mediate the regulation of exploratory behavior in the rat. Eur J Pharmacol 193:379-381.
20. B antagonists on activity in the black/ white exploration model of anxiety in mice. Psychiatry Behav 54:689-693.
21. Hughes J, Boden P, Costall B, Domeney A, Kelly E, Honvell DC, Hunter JC, Pinnock RD, Woodruff GN. 1990. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sei USA 87:6728-6732.
22. Hughes J, Hunter JC, Woodruff GN. 1991. Neurochemical actions of CCK underlying the therapeutic potential of CCK-B antagonists. Neuropeptides 19:85-89.
23. B receptor ligands in a validated stimulation of panic anxiety in rats. Nerupsychopharmacology 6:291-298.
24. Kramer MS, Cutler NR, Ballenger JC, Patterson WM, Mendels J, Cheriault A, Shrivastava R, Matzura WD, Lines C, Reines S. 1995. A placebo-controlled trial of L-365,260, a CCK-B antagonist, in panic disorder. Biol Psychiatry 37:462-466.
25. Lydiard RB, Ballenger JC, Larasa MT, Fossey MD, Beinford ML. CSF cholecystokin concentration in patients with panic disorder and in normal comparison subjects. Am J Psychiatry 149:691-693.
26. Melton PM, Riley AL. 1993. An assessment of the interaction between cholecystokinin and the opiates within a drug discrimination procedure. Pharmacol Biochem Behavior 46:237-242.
27. Paviasevic S, Bednar I, Qureshi GA, Sodersten P. 1993. Brain cholecystokinin tetrapeptide levels are increased in a rat model of anxiety. Neuroreport 5:225-228.
28. Phillips GD, Le Noury J, Wolterink G, Donselaar-Wolterink I, Robbins TW, Everitt BJ. 1993. Cholecystokini-dopamine interaction within the nucleus accumbens in the control over behavior by conditioned reinforcement. Behav Brain Res 55:232-236.
29. Pitman RK. 1993. Once bitten, twice shy: beyond the conditioning model of PTSD. Biol Psychiatry 33:145-146.
30. Rasmussen K, Helton DR, Berger JE, Scearce E. 1993. The CCK-B antagonist Ly 288513 blocks effects of diazepan withdrawal on auditory startle. Neuro report 5:154-156.
31. Rex A, Fink H, Marsden CA. 1994. Effects of BOC-CCK-4 and L-365-260 on cortical %-HT release in Guinea Pigs on exposure to the elevated plus maze. Neuropharmacology 33: 559-565.
32. Van Alegen HJGM , Westenberg HGM , den Boer JA, Kahn RS. 1996. Cholecystokinin in anxiety. Eur Nerupsychopharmacol 6:263-280.
33. Vasar E, Lang A, Harro J. 1994. Evidence for potentiation by CCK antagonists of the effect of cholecystokinin octapeptide in the elevated plus-maze. Neuropharmacology 33:729-735.
34. Wilson J, Watson WP, Little HJ. 1998. CCKB antagonists protect against anxiety-related behaviour produced by ethanol withdrawal, measured using the elevated plus maze. Psychopharmacology 137:120-131.
35. Yamamoto T, Nozaki-Taguchi N. 1996. The effects of intrathecally administered FK480, a choIecystokinin-A receptor antagonist, and YA1022, a cholecystokinin-B receptor antagonist, on the formalin test in the rat. Anesth Analg 83:107-113.